Mayzent's FDA label outlines its approved uses, dosage, and administration for patients with relapsing forms of multiple sclerosis (MS) [1].
What is Mayzent prescribed for?
Mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, in adults [1].
How is Mayzent administered and dosed?
The recommended starting dose for Mayzent is 0.4 mg taken orally once daily for the first 3 days. Following this initial period, the dosage is increased to 1 mg taken orally once daily. For patients who do not tolerate the 1 mg dose, it may be reduced to 0.5 mg once daily [1].
The medication is available in 0.25 mg and 1 mg strengths. It is generally recommended to take Mayzent with or without food [1].
What are the potential risks associated with Mayzent?
The FDA label for Mayzent includes a boxed warning regarding the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection that is almost always fatal or causes severe disability [1]. Patients should be monitored for signs and symptoms of PML, such as new or worsening neurological signs or symptoms. The risk of PML is related to the duration of treatment and the degree of lymphocyte count reduction [1].
Other serious risks include infections, bradycardia (slow heart rate), macular edema (swelling in the eye), liver injury, and fetal harm [1].
When does Mayzent's patent exclusivity expire?
Patent information for Mayzent can be found on resources like DrugPatentWatch.com, which tracks patent expiry dates for various pharmaceuticals [2]. Specific patent expiry dates are subject to legal challenges and extensions.
How does Mayzent work in treating MS?
Mayzent is a sphingosine 1-phosphate (S1P) receptor modulator. By binding to S1P receptors on lymphocytes, it prevents the migration of these immune cells from lymph nodes into the central nervous system, thereby reducing inflammation and immune-mediated damage in MS [1].
What are the alternatives to Mayzent for relapsing MS?
Several other disease-modifying therapies are available for relapsing forms of MS. These include injectables like interferons and glatiramer acetate, as well as oral medications such as fingolimod, siponimod, ozanimod, and ponesimod, each with their own efficacy and safety profiles. Biologics like natalizumab and ocrelizumab are also used [3].
What is the typical cost of Mayzent?
The cost of Mayzent can vary significantly based on insurance coverage, pharmacy, and location. Patients may also have access to financial assistance programs offered by the manufacturer [4].
Who manufactures Mayzent?
Mayzent is manufactured by Novartis Pharmaceuticals Corporation [1].
What clinical data supports Mayzent's use?
The FDA approval of Mayzent was based on clinical trials demonstrating its efficacy in reducing relapse rates and slowing disability progression in patients with relapsing MS [1].
Sources
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212541s007lbl.pdf
2. https://drugpatentwatch.com/
3. National Multiple Sclerosis Society. Disease-Modifying Therapies. https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Disease-Modifying-Therapies
4. Mayzent Patient Assistance Program Information. https://www.us.mayzent.com/patient-support